Private company
Enumeral
Massachusetts biotechnology company, 2009–2018
Enumeral was a Cambridge, Massachusetts-based biotechnology company which developed monoclonal antibody immunotherapies through an 'immunoprofiling' platform that allowed it to scan the human immune microenvironment and identify and validate potential drug candidates. The company filed for Chapter 11 bankruptcy and arranged to sell its assets to Xoma Corporation in January 2018.2 Wikipedia text CC BY-SA 4.0
Last updated Oct 21, 2026.
Overview
See how the biggest companies compare on our leaderboards
Enumeral was a Cambridge, Massachusetts-based biotechnology company which developed monoclonal antibody immunotherapies through an 'immunoprofiling' platform that allowed it to scan the human immune microenvironment and identify and validate potential drug candidates. The company filed for Chapter 11 bankruptcy and arranged to sell its assets to Xoma Corporation in January 2018.2
Products and brands
- monoclonal antibody
Listed on Wikidata.1
Timeline
- 2009Founded Founded1
Links
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataEnumeral on Wikidata
- 2WikipediaEnumeral on Wikipedia